Arno Therapeutics Inc (OTCMKTS:ARNI) a clinical stage biopharmaceutical company announced that it obtained Notice of Allowance from the USPTO for two filed patent applications linked to its main oncology product candidate, named as ‘onapristone.’

The first patent is about onapristone polymorph structures and means of use, while the second patent comprises diagnostic systems and methods for treating and identifying anti-progestin sensitive tumors. Together, the patents support the intellectual property shielding onapristone.

The expert view

Alex Zukiwski, MD, the Chief Executive of Arno Therapeutics, said that the two patents are vital for the protection of drug candidate onapristone, as company continue advancing its research through two clinical studies, a Phase 2 trial in women with recurrent or metastatic endometrioid tumors that express APR, and a separate Phase 1/2 clinical study in men suffering with castration-resistant prostate cancer.

Both the studies are in enrollment phase. By shielding the polymorph forms and means of use of the diagnostic measures as well as drug for treating and identifying anti-progestin sensitive tumors, the company now has better control over the prospect of this potential and unique vital new hormonal treatment.

The drug

Arno’s Onapristone can be defined as an oral and anti-progestin hormone blocker. It has demonstrated in previous Phase 2 clinical studies considerable anti-tumor activity in women suffering with breast cancer. In pre-clinical studies, onapristone has proved to block the activation of PR which is assumed as a process that inhibits the enlargement of APR driven breast, and other gynecological tumors. The study was not sponsored by Arno.

In last trading session, the stock price of ARNI surged more than 18% to close the trading session at $0.940. The gain came at a share volume of 1.41 million compared to average share volume of 131,565. The high for the day was $1 while low was $0.71.

Previous articleValmie Resources Inc (OTCBB:VMRI) Assessing UAV Tech Outside U.S.
Next articleWhat Cellceutix Corp (OTCMKTS:CTIX) Has To Say On Prurisol?
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.